Core Viewpoint - Juzi Biotechnology (02367) experienced a rebound of over 8%, with a current price of HKD 41.9 and a trading volume of HKD 400 million [1] Group 1: Shareholder Activity - Juzi Holding, the controlling shareholder, purchased 500,000 shares of the company on the announcement date, amounting to approximately HKD 19.3 million [1] - Since the disclosure of the buyback plan on June 9, 2025, Juzi Holding has cumulatively acquired 3.666 million shares, investing a total of about HKD 178 million [1] - Following these purchases, Juzi Holding's shareholding increased to 585 million shares, representing 54.61% of the company's total issued shares, with intentions to further increase holdings based on market conditions and regulatory requirements [1] Group 2: Market Analysis - Citigroup recently released a report indicating that the market's reaction to Juzi Biotechnology's pre-sale performance decline during the Double 11 event, particularly in Li Jiaqi's live-streaming sales, is overly pessimistic [1] - Although Li Jiaqi's live-streaming sales are a significant indicator for Double 11 performance, the contribution from other KOLs and the company's own live-streaming efforts has been rapidly increasing, reducing reliance on any single influencer [1] - Despite the competitive landscape, there has been no negative feedback from customers regarding the company's products or brand [1] - Given the low base this year, Citigroup anticipates a recovery in sales for Juzi Biotechnology in the fiscal year 2026, maintaining that the company's valuation remains attractive [1]

Core Viewpoint - Jinsong New Materials (300849) has received an administrative penalty notice for information disclosure violations, resulting in fines for the company and its executives [2][3]. Group 1: Administrative Penalties - The company was fined 1.5 million yuan, and the chairman, Ruan Rongtao, was also fined 1.5 million yuan for the violations [2]. - The former general manager, Ruan Qijiang, and the chairman of the supervisory board, Xia Shuliang, received warnings and fines of 1 million yuan each, while the former vice president and director, Ruan Cenghong, received a warning and a 500,000 yuan fine [2]. Group 2: Violations Details - The main violation involved failing to disclose related party transactions in the 2022 annual report, specifically a construction contract with Zhejiang Hongxiang for a project valued at 120 million yuan, which accounted for 18.6% of the company's audited net assets for that year [3]. - The contract was improperly awarded to Ruan Zhongyan, the nephew of Ruan Rongtao, without proper disclosure, constituting a related party transaction [3]. Group 3: Company Response and Governance - The company held a board meeting on April 29, 2023, to retroactively approve the related party transaction, which was later confirmed by a shareholder meeting with a 99.97% approval rate [4]. - The company has committed to improving internal governance, enhancing operational standards, and ensuring compliance with information disclosure regulations to protect shareholder interests [4]. Group 4: Company Background - Jinsong New Materials has over 20 years of experience in the production and sale of cosmetic packaging materials, offering a wide range of products, including over 1,000 specifications for well-known brands [5]. - The company was listed on the Growth Enterprise Market in July 2020, raising funds for projects aimed at increasing production capacity [5].

Core Viewpoint - Juzi Biotechnology (02367.HK) is experiencing significant stock price volatility due to poor sales performance in live streaming, leading to a decline in market confidence and a substantial drop in stock value [1][2] Group 1: Shareholding and Stock Performance - Juzi Holding, the controlling shareholder, purchased 500,000 shares for approximately HKD 19.3 million, increasing its total holdings to 5.85 billion shares, representing 54.61% of the company's issued shares [1] - The company's stock price recently fell from a high of HKD 87.1 per share on May 20 to a low of HKD 56.2 per share by June 9, resulting in a market value loss exceeding HKD 30 billion [1] - The latest stock price is HKD 38.62, with a market capitalization of HKD 41.36 billion [1] Group 2: Financial Performance - Juzi Biotechnology reported a revenue of HKD 3.113 billion for the first half of 2025, a year-on-year increase of 22.5%, and a net profit of HKD 1.182 billion, up 20.6% [2] - The projected revenue for 2024 is HKD 5.538 billion, reflecting a 57.2% year-on-year growth, with a net profit forecast of HKD 2.061 billion, a 42.4% increase [2] - The company has significantly increased its sales and distribution expenses, with a projected expenditure of HKD 2.008 billion in 2024, up 72.51% from HKD 1.164 billion in 2023 [2] Group 3: Market Position and Challenges - Juzi Biotechnology is a leading player in the restructured collagen market, with its brand Kefu Mei achieving rapid growth and becoming a top domestic brand [2] - The company has faced challenges due to ongoing disputes regarding the authenticity of collagen content, which has affected consumer confidence and market perception [1]

Investment Rating - The industry investment rating is "stronger than the market" (预计6个月内，行业指数表现强于沪深300指数5%以上) [63] Core Insights - The beauty industry is currently in a rational development phase, with increasing consumer power and competitiveness of domestic brands, particularly those that can quickly respond to consumer needs [3][59] - The 2025 edition of "All Girls' Offer" features 88 brands and 166 SKUs, with a significant increase in participation from domestic brands, reflecting the rise of domestic products and the pursuit of greater exposure by emerging brands [3][10][59] - The negotiation mechanism for this season's offers is more consumer-friendly, with deeper discounts, new products upgraded without price increases, and combinations that better meet consumer needs [3][59] Summary by Sections Consumer Power and Market Dynamics - Consumer power has significantly increased, indicating a "buyer’s market" in the current beauty industry [3][59] - The 2025 offer introduced a competitive mechanism where consumer votes account for 60% of the total, intensifying brand competition [10][59] Brand Participation and Offer Characteristics - This season's offers include a higher proportion of domestic and mass-market brands, with 32 domestic brands and 20 international brands participating [3][10][59] - The offers are characterized by deeper discounts, new products with no price increases, and simpler, cleaner bundles for returning customers [3][25][59] International and Domestic Brand Competition - International brands are continuously upgrading their products, while domestic brands are enhancing their research capabilities and actively participating in offer negotiations [3][42][45] - Emerging domestic brands are seeking greater exposure and sales growth by participating in the offers [53][59] Investment Recommendations - The report suggests focusing on brands such as 毛戈平, 珀莱雅, 上美股份, 爱美客, 贝泰妮, 润本股份, 巨子生物, and 丸美股份, which are well-positioned in the current market [3][59]

个股方面，广和通跌11.72%，小米集团跌0.26%，中石化油服涨4.76%，黑芝麻智能涨4.74%，老铺黄金 跌8.21%，巨子生物跌1.53%，保利物业涨0.29%，工商银行涨0.17%，建设银行跌0.13%，中国石油股份 涨1.15%，中铝国际涨30.52%，荣昌生物跌4.62%，小鹏汽车跌1.84%，中国移动跌0.88%。 成交额前三的个股中，阿里巴巴跌1.94%，成交超109亿港元；泡泡玛特涨2.40%，成交超78亿港元；信 达生物跌1.96%，成交超62亿港元。 转自：新华财经 当日恒指低开129.93点，开报25897.62点，开盘后先有小幅震荡上行，午市休市前下跌至当日最低 25653.75点，午后虽有上涨但拉升动力不足，最终恒指跌245.78点，主板成交超2275亿港元。截至收 盘，上涨股票816只，下跌1286只，收平1097只。当日，港股通（南向）净流入超过100亿港元。 整体来看，多数板块下跌，银行、石油与天然气、航空等股多为上涨，有色金属、建材水泥、房地产等 股有涨有跌，生物医药、科网、新能源汽车、保险、券商、黄金、煤炭等股多有下跌。 新华财经香港10月22日电（记者林迎楠）22日港 ...

Core Points - Juzi Holding Co., Ltd, the controlling shareholder of the company, has purchased a total of 500,000 shares in the market, amounting to approximately HKD 19.3 million, to support the company's sustainable and healthy development [1] - Since the announcement of the share purchase plan on June 9, 2025, Juzi Holding has acquired a total of 3,666,600 shares, with a total investment of about HKD 178 million [1] - Following this latest purchase, Juzi Holding now holds a total of 584,771,535 shares, representing 54.61% of the company's total issued shares [1] - Juzi Holding may continue to increase its shareholding based on market conditions and applicable regulatory requirements [1]

巨子生物(02367)公布，董事会接获公司控股股东Juzi Holding Co.,Ltd(Juzi Holding)通知，基于对公司未 来发展的强烈信心，为促进公司持续、稳定、健康发展，维护广大公众投资者利益，于本公告日期， Juzi Holding于市场内合共购入50万股公司股份，本次增持金额合计约为1930万港元(不包括佣金及其他 开支)。自2025年6月9日发布增持计划后，截至本公告日期，Juzi Holding于市场内共购入366.66万股公 司股份，增持金额合计约为1.784亿元港币(不包括佣金及其他开支)。紧随本次增持后，于本公告日期， JuziHolding合共持有公司584,771,535股股份，占公司已发行总股数的54.61%。JuziHolding可能会根据市 场状况和适用的监管要求，不时进一步增持公司股份。 ...

本 公 司 股 東 及 有 意 投 資 者 於 買 賣 本 公 司 股 份 時 務 請 審 慎 行 事。 承董事會命 GIANT BIOGENE HOLDING CO., LTD 巨子生物控股有限公司 （於 開 曼 群 島 註 冊 成 立 的 獲 豁 免 有 限 公 司） （股 份 代 號：2367） 自願性公告 控股股東增持股份 本公告乃由巨子生物控股有限公司（「本公司」）自 願 作 出。兹 提 述 本 公 司 日 期 為 2025年6月9日 的 公 告，內 容 有 關 控 股 股 東 增 持 本 公 司 股 份 的 計 劃。 本公司董事會（（「董事會」）接獲本公司控股股東Juzi Holding Co., Ltd（「Juzi Holding」） 通 知，基 於 對 本 公 司 未 來 發 展 的 強 烈 信 心，為 促 進 本 公 司 持 續、穩 定、健 康 發 展，維 護 廣 大 公 眾 投 資 者 利 益，於 本 公 告 日 期，Juzi Holding於市場內合共購入 500,000股本公司股份（「本次增持」），本 次 增 持 金 額 合 計 約 為19.3百萬港元（不 包 括 佣 金 及 其 他 ...

Market Overview - The Hong Kong stock market saw a positive performance on October 21, with the Hang Seng Index rising by 0.65% to 26,027.55 points, the Hang Seng Tech Index increasing by 1.26% to 6,007.94 points, and the National Enterprises Index up by 0.76% to 9,302.66 points [1] - The Hang Seng Index opened 301.41 points higher at 26,160.24 points, reached a peak of 26,367.35 points during the day, and closed with a gain of 168.72 points. The main board recorded a trading volume exceeding 264.6 billion HKD [1] - There were 1,315 stocks that rose, 884 that fell, and 1,000 that remained unchanged by the end of the trading day [1] Sector Performance - Most sectors experienced gains, particularly in chips, AI healthcare, insurance, and brokerage stocks. However, sectors such as oil and gas, building materials, and banks showed mixed results, while gold, non-ferrous metals, coal, and new consumption sectors mostly declined [1] Notable Stocks - Individual stock movements included: - Jushuitan surged by 23.86% - Xiaomi Group fell by 1.44% - Meituan decreased by 0.16% - Industrial and Commercial Bank of China rose by 0.68% - China Construction Bank increased by 0.90% - China Petroleum & Chemical Corporation gained 1.43% - Giant Bio fell by 4.01% - Yaojie Ankang dropped by 11.48% - Zijin Mining decreased by 0.37% - Ding Shi Capital surged by 33.12% - Tencent Holdings rose by 0.48% - Geely Automobile increased by 3.23% - NIO rose by 2.78% - CATL increased by 3.03% [1] Top Traded Stocks - The top three traded stocks included: - Alibaba, which rose by 1.98% with a trading volume exceeding 18.5 billion HKD - Pop Mart, which fell by 8.08% with a trading volume exceeding 9.8 billion HKD - SMIC, which increased by 3.13% with a trading volume exceeding 9.1 billion HKD [2]

每经AI快讯，巨子生物(02367.HK)再跌超4%，较年内高点85.79港元已腰斩，截至发稿，跌4.01%，报 39.22港元，成交额7.45亿港元。 ...